Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003910 · ClinicalTrials.gov registry record · Phase 2
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT00003910 is a Phase 2 study that was terminated before completion, run by Eastern Cooperative Oncology Group. The registered enrollment target is 59 participants.
The verdict
NCT00003910, a Phase 2 study, was terminated before completion, sponsored by Eastern Cooperative Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of methotrexate with or without cyclophosphamide in treating patients who have lymphocytic leukemia with neutropenia or anemia.
Interventions
- DRUG Cyclophosphamide
- DRUG Prednisone
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 1999-09-15 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003910
The ClinicalTrials.gov registry entry for NCT00003910 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00003910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003910 about?
NCT00003910 is a clinical study titled "Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of methotrexate with or without cyclophosphamide in treating patients who have lymphocytic leukemia with neutropenia or anemia.
What is the current status of trial NCT00003910?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 1999-09-15. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00003910?
The interventions under investigation include: Cyclophosphamide (DRUG), Prednisone (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00003910?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.